Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial

Bibliographic Details
Title:	Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Authors:	Randon, Giovanni ^a, Lonardi, Sara ^b, Fassan, Matteo ^{c, d}, Palermo, Federica ^a, Tamberi, Stefano ^e, Giommoni, Elisa ^f, Ceccon, Carlotta ^c, Di Donato, Samantha ^g, Fornaro, Lorenzo ^h, Brunetti, Oronzo ⁱ, De Vita, Ferdinando ^j, Bittoni, Alessandro ^k, Chini, Claudio ^l, Spallanzani, Andrea ^m, Nappo, Floriana ^b, Bethaz, Valerie ⁿ, Strippoli, Antonia ^o, Latiano, Tiziana ^p, Cardellino, Giovanni Gerardo ^q, Giuliani, Francesco ^{i, r}, Morano, Federica ^a, Niger, Monica ^a, Raimondi, Alessandra ^a, Prisciandaro, Michele ^a, Pircher, Chiara Carlotta ^a, Sciortino, Carolina ^a, Marchesi, Silvia ^a, Garattini, Silvio Ken ^{a, q}, Airò, Giulia ^{a, s}, Miceli, Rosalba ^t, Di Bartolomeo, Maria ^a, Pietrantonio, Filippo ^{a, *}
Source:	In The Lancet Oncology December 2024 25(12):1539-1550
Database:	ScienceDirect